Xeris Biopharma Holdings, Inc. (XERS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. John P. Shannon
|
Chairman & CEO | 1.36M | 543.39k | 1962 |
|
Mr. Kevin McCulloch
|
President & COO | 913.53k | -- | 1964 |
|
Mr. Steven M. Pieper
|
Chief Financial Officer | 796.18k | -- | 1977 |
|
Ms. Beth P. Hecht J.D.
|
Chief Legal Officer & Corporate Secretary | 817.37k | -- | 1964 |
|
Dr. Anh T. Nguyen M.B.A., M.D.
|
Chief Medical Officer | 653.7k | -- | 1975 |
Xeris Biopharma Holdings, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 435
Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Xeris Biopharma Holdings, Inc. Earnings Date
